Cover Image

Salvage Therapy with Intraoperative Cesium-131 for Recurrent Ovarian Cancer

A. Gabriella Wernicke, Stacy Jeong, Shoshana Taube, Bhupesh Parashar, Lucy Nedialkova, Fridon Kulidzhanov, Albert Sabbas, Eloise Chapman-Davis, Thomas Caputo, Kevin Holcomb

Abstract


Recurrent ovarian cancer is considered incurable and the current standard of treatment (surgery and chemotherapy) is palliative. For isolated, localized recurrent tumor, brachytherapy with Cesium-131 is a promising treatment because of its localized radiation yet limited exposure to healthy tissue. Compared to its predecessors, Cs-131 has a very short half-life, allowing for highly localized radiation that decreases toxicity of treatment and convenience for the patient. Our case shows a patient diagnosed with recurrent ovarian cancer metastatic to the right paraaortic odes. The first successful application of Cs-131 brachytherapy was performed with 100% local control without added toxicity. This shows a favorable addition to the current standard of care for highly localized ovarian cancers.


Keywords


Brachytherapy; Cesium-131; Recurrent Ovarian Cancer

References


Cho KR, Shih LM. Ovarian Cancer. Annu Rev Pathol. 2009, 4:287-313

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H. Endometroid Epithelial Ovarian Cancer. Cancer. 2008, 112(10):2211-2220

Mann WJ, Chalas E, Valea FA. Cancer of the ovary, fallopian tube, and peritoneum: Staging and initial surgical management. Waltham, MA: UpToDate; 2015 November. Available from: http://www.uptodate.com/contents/cancer-of-the-ovary-fallopian-tube-and-peritoneum-staging-and-initial-surgical-management?source=see_link#H403752

Mahantshetty U, Jamema S, Engineer R, Deshpande D, Sarin R, Fogliata A, Nicolini G, Clivio A, Vanetti E, Shrivastava S, Cozzi L. Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation. Radiation Oncology. 2010, 5:106

Dembo AJ. Epithelial Ovarian Cancer: The Role of Radiopathy. Radiation Oncology. 1992, 22(5): 835-845

Skirnisdottir I, Nordqvist S, Sorbe B. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past? Oncol Rep. 2005, 14(2):521-529

Kehwar TS. Use of Cesium-131 radioactive seeds in prostate permanent implants. J Med Phys. 2009, 34(4):191-193

Parashar B, Wernicke AG, Pavese A, Singh P, Trichter S, Sabbas A, Kutler DI, Kuhel W, Port JL, Lee PC, Nori D, Chao KSC. Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff. Brachytherapy. 2011, 10(6):508-513

Henschke UK, Lawrence DC. Cesium-131 Seeds for Permanent Implants. Radiology. 1965 December; 86(6):1117-1119

Wooten CE, Randall M, Edwards J, Aryal P, Luo W, Feddock J. Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies. Gynecol Oncol. 2014, 133(2):268-273


Full Text: PDF

Refbacks

  • There are currently no refbacks.


AJCC-REP (ISSN 2572-5742)Copyright © 2012-2018. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States